Samjin Pharmaceutical Signs Agreement with Aribio Lab for Joint Vaccine Development and Commercialization
Collaboration on the Development of Herpes Zoster and Hepatitis B Vaccines
Samjin Pharmaceutical announced on June 1 that it has signed a strategic memorandum of understanding (MOU) with Aribio Lab for the joint development and commercialization of vaccines for herpes zoster and hepatitis B.
From the left, Sangjin Kim, President of Samjin Pharmaceutical, and Jaejun Jung, CEO of Aribio Lab, are posing for a commemorative photo at the strategic business alliance signing ceremony. Samjin Pharmaceutical
View original imageThe two companies plan to collaborate on vaccine development and commercialization by combining Aribio Lab's immune enhancement platform technology with Samjin Pharmaceutical's research and development, as well as sales and marketing capabilities.
Under this agreement, the companies will explore ways to cooperate in the domestic sales of the herpes zoster and hepatitis B vaccines currently being developed by Aribio Lab. They will also pursue joint research and development of vaccine pipelines utilizing the immune enhancement platform technologies 'L-pampo' and 'Lipo-pam'. Aribio Lab is currently conducting phase 2 clinical trials for its recombinant herpes zoster vaccine, 'CVI-VZV-001'.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Sangjin Kim, President of Samjin Pharmaceutical, stated, "By combining the research and development capabilities and commercialization expertise of both companies, we have established a foundation to create synergy in the vaccine field." Jaejun Jung, CEO of Aribio Lab, added, "Through the development of herpes zoster and hepatitis B vaccines, as well as next-generation immune enhancement technologies, we aim to strengthen the competitiveness of domestic vaccines."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.